Harare – Zimbabwe’s medicines regulator has ordered the urgent recall of a widely used antibiotic after quality concerns were identified during routine testing, raising alarms over its effectiveness and implications for patient care.
The Medicines Control Authority of Zimbabwe (MCAZ) confirmed that Azithromycin 500mg USP Tablets, Batch Number 24050191, are being withdrawn from circulation after a defect was detected during stability testing.
Quality concerns trigger recall
According to MCAZ, laboratory findings showed that the affected batch may fail to maintain its required potency over time. This raises the risk that the medication may not deliver its intended therapeutic effect when used by patients.
Azithromycin is commonly prescribed to treat a wide range of bacterial infections, including respiratory tract infections, skin conditions, ear infections, and certain sexually transmitted infections. Its effectiveness depends on maintaining strict pharmaceutical quality standards throughout its shelf life.
Risks to treatment outcomes
Medical experts warn that substandard or degraded antibiotics can lead to treatment failure, prolong illness, and increase the likelihood of complications. Of particular concern is the potential contribution to Antimicrobial resistance, a growing global health threat in which bacteria become resistant to standard treatments.
Although no confirmed adverse reactions linked specifically to the recalled batch have been reported, the authority stressed that the recall is a precautionary measure aimed at preventing harm.
Guidance for patients and healthcare providers
MCAZ has instructed pharmacies, hospitals, and healthcare providers to immediately halt the distribution and dispensing of the affected batch and to isolate existing stock for return to suppliers.
Patients who may already have the medication are advised to check the batch number on their packaging and seek medical advice if it matches the recalled product. Health authorities caution against stopping antibiotic treatment without professional guidance, as this may worsen infections or complicate recovery.
Importance of post-market surveillance
The incident underscores the critical role of post-market surveillance systems, which ensure that medicines continue to meet safety and quality standards after they have been released into the market. Stability testing is a key part of this process, evaluating how medicines perform under different environmental conditions over time.
Global health bodies such as the World Health Organisation have consistently emphasised the importance of robust regulatory oversight to prevent the circulation of substandard or ineffective medicines.
Supply pressures and ongoing investigations
Healthcare providers in Zimbabwe may need to prescribe alternative antibiotics while the recall is in effect, raising concerns about potential short-term supply constraints, particularly in public health institutions.
MCAZ has indicated that investigations are underway to determine the root cause of the defect, including whether it originated during manufacturing, storage, or distribution. The authority has reaffirmed its commitment to protecting public health and maintaining confidence in the country’s pharmaceutical supply chain.
